Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS)

Study characteristics: - randomized, placebo-controlled trial - 6,105 individuals with previous stroke or TIA - 172 centres in Asia, Australasia, and Europe - 30% of participants were women - 4 years follow-up Groups: - perinodopril 4 mg QD plus placebo - perinodopril 4 mg QD plus diuretic (indapamide) - placebo Results: 1) 10% of treated groups suffered stroke vs 14% of placebo group 2) stroke risk reduction occurred regardless of whether subject was hypertensive 3) subjects treated with perinodopril plus indapamide had significantly fewer recurrent strokes than subjects treated with placebo (8% vs 14%) 4) perinodopril alone afforded no benefit for stroke reduction 5) the antihypertensive effect of perinodopril plus indapamide was greater than that of perinodopril alone 12/4 mm Hg vs 5/3 mm Hg

References

PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001 Sep 29;358(9287):1033-41. Erratum in: Lancet 2001 Nov 3;358(9292):1556. Lancet 2002 Jun 15;359(9323):2120. Summary for patients in: Can Fam Physician. 2002 Oct;48:1625-9. PMID: 11589932